Moreover, there are few studies examining the immune properties of gliomas, particularly in the context of immunosuppressive processes, thus making it difficult for us to objectively recognize its role and deeply restricting the clinical translation of CD93-targeted therapies for glioma. Here, CD93 is linked to central nervous system cancer.